Results are expected late 2012 a significant proof-of-concept milestone for this unique, Staphylococcus specific antibiotic, AFN-1252 represent.. The objectives of the study are the validity, -1252. Of 200 mg oral confirm AFN-1252 twice daily for 5-14 days in patients with severe, suspected staphylococcal skin infections in the outpatient or emergency room settings recruited doses. The study evaluates both traditional endpoints at the end of treatment and early endpoints currently recommended by the FDA. – ‘We are pleased with the ease and speed of patient enrollment in our study are very pleased,’said Dr.
Both the old and the new class of drugs for inhibition of enzymes which break down based potent natural chemical mediators.Inceoglu, hammock, Schebb and Wagner paper with veterinary anesthesiologist Robert Brosnan, associate professor of surgical and radiological sciences, School of Veterinary Medicine, co-author, and Christophe Morisseau, Arzu Ulu, Christine Hegedus and Tristan Rose, Department of Entomology and the Cancer Center. Continue reading